PsyIndex Weekly Update – June 21, 2021 – June 25, 2021

PsyIndex Weekly Update

June 21, 2021 – June 25, 2021

The PsyIndex extended its losses last week, although there were signs of a rebound toward the end of the week. With a combination of new public listings and favorable regulatory developments, the industry has a number of upcoming catalysts that investors will be watching closely.

Market Performance

Weekly Performance: $129.39 (-3.64%)

Powered by

CFN Enterprises Inc. (OTCQB: CNFN)

Top Gainers

Cybin Corp.
(NEO: CYBN)
2.720 +0.590 (27.70%)
PharmaTher Holdings Inc.
(CSE: PHRM)
0.890 +0.180 (25.35%)
EGF Theramed Health Corp.
(CSE: TMED)
0.095 +0.015 (18.75%)

Top Decliners

Psyched Wellness Inc.
(CSE: PSYC)
0.205 -0.060 (-22.64%)
eHave Inc.
(OTC: EHVVF)
0.050 -0.014 (-21.87%)
Novamind Inc.
(CSE: NM)
0.960 -0.200 (-17.24%)

View All Index Constituents

Corporate News, Deals & Listings

Filament Health Corp. announced it has received final approval to list its common shares on the NEO and began trading on June 24, 2021 under the symbol NEO: FH. Press Release
Field Trip Health Ltd. (TSX: FTRP) announced its fiscal fourth-quarter financial results, as the largest vertically integrated psychedelics company. Press Release
Silo Wellness Inc. (CSE: SILO) announced the launch of Marley One, the first global functional and psychedelic mushroom consumer brand, in collaboration with the family of legendary musician Bob Marley. Press Release
Revive Therapeutics Inc. (CSE: RVV) announced that its shares were approved to list on the OTCQB. Press Release

Industry Developments

The future of psychedelic medicine might skip the trip. via Forbes
A new psychedelics ETF just launched: Here’s why that’s big news. via Motley Fool
California State Senate passes psychedelic legislation in latest wave. via Mondaq

Visit the PsyIndex